Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

Completed · Phase 1

Conditions studied: HIV Infections, HIV Seronegativity

In brief

The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.

Key facts

Study ID

NCT00002231

Run by

Wyeth-Lederle Vaccines

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are 18 - 60 years old.
• Are HIV-negative and in good health.
• Are able to understand how infections such as HIV are spread.
• Agree to use effective methods of birth control during the study.

You may not qualify if…

• You will not be eligible for this study if you:
• Have hepatitis B or C.
• Have any condition that may prevent you from completing the study.
• Are allergic to bupivacaine, vaccines, or certain local anesthetics.
• Have taken certain medications or have received certain therapies that may affect your immune system.
• Have an immune system disorder or have received therapy for an immune system disorder.
• Have been exposed to HIV within 6 months prior to study entry.
• Have received an experimental HIV vaccine or any other experimental treatment within 30 days prior to study entry.
• Have received blood transfusions within 6 months prior to study entry.
• Abuse alcohol or drugs or have an uncontrolled psychiatric disorder.
• Are pregnant or breast-feeding.

Where it is running

• Univ of Pennsylvania Med Ctr — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.